US Patent Issued to Aragon Pharmaceuticals on Oct. 21 for "Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer" (California Inventor)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. RE50,642, issued on Oct. 21, was assigned to Aragon Pharmaceuticals Inc. (Los Angeles).

"Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer" was invented by Isan Chen (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens."

The patent was filed on Aug. 26, 2022, under Application No. 17/896,658.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1...